March - Behavioral Health Care Services
... After a single intramuscular (IM) injection of long-acting risperdone, there is a small initial release of the drug followed by a lag time of three weeks. The main release of the drug starts from three weeks onward, is maintained for four to six weeks, and subsides by seven weeks following the IM in ...
... After a single intramuscular (IM) injection of long-acting risperdone, there is a small initial release of the drug followed by a lag time of three weeks. The main release of the drug starts from three weeks onward, is maintained for four to six weeks, and subsides by seven weeks following the IM in ...
Prescribing Information
... 1,200 mg provided no additional benefit compared with the 600-mg dose, but caused an increase in adverse reactions [see Adverse Reactions (6.1)]. If the dose is not taken at the recommended time, the next dose should be taken the following day as prescribed. 2.2 Postherpetic Neuralgia The recommende ...
... 1,200 mg provided no additional benefit compared with the 600-mg dose, but caused an increase in adverse reactions [see Adverse Reactions (6.1)]. If the dose is not taken at the recommended time, the next dose should be taken the following day as prescribed. 2.2 Postherpetic Neuralgia The recommende ...
Kensington Veterinary Hospital Distichia and Ectopic Cilia
... There is no known cause for the development of distichia or ectopic cilia. Several breeds are over-represented, indicating that there may be one or more heritable factors that lead to the development of these abnormal eyelashes. What are the common clinical signs? In many cases, distichia are incide ...
... There is no known cause for the development of distichia or ectopic cilia. Several breeds are over-represented, indicating that there may be one or more heritable factors that lead to the development of these abnormal eyelashes. What are the common clinical signs? In many cases, distichia are incide ...
AusPAR: Imatinib (as mesylate)
... by the KIT oncogene. Imatinib inhibits proliferation and induces apoptosis in GIST cells expressing an activating KIT mutation. Most GISTs (75-80%) have activating KIT mutations.1 Besides GIST, imatinib is registered for several other indications. The drug is well absorbed after oral administration, ...
... by the KIT oncogene. Imatinib inhibits proliferation and induces apoptosis in GIST cells expressing an activating KIT mutation. Most GISTs (75-80%) have activating KIT mutations.1 Besides GIST, imatinib is registered for several other indications. The drug is well absorbed after oral administration, ...
The Toxicology of HMG—CoA Reductase Inhibitors
... metabolite of compactin in dogs and its introduction was followed by fluvastatin, atovastatin, cerivastatin, and most recently rosuvastatin. Cerivastatin was removed from the market in 2000 as a result of significant toxicity (myopathy) that will be described in subsequent sections of this paper. As ...
... metabolite of compactin in dogs and its introduction was followed by fluvastatin, atovastatin, cerivastatin, and most recently rosuvastatin. Cerivastatin was removed from the market in 2000 as a result of significant toxicity (myopathy) that will be described in subsequent sections of this paper. As ...
references - Rajiv Gandhi University of Health Sciences
... Gentamicin is an important aminoglycoside antibioticcommonlyused in treating lifethreatening gram-negative infections6.However its usefulness is limited by signs of nephrotoxicity, which may occur in 13-30% of treated patients7. Lipid peroxidation may occur in the course of gentamicin administratio ...
... Gentamicin is an important aminoglycoside antibioticcommonlyused in treating lifethreatening gram-negative infections6.However its usefulness is limited by signs of nephrotoxicity, which may occur in 13-30% of treated patients7. Lipid peroxidation may occur in the course of gentamicin administratio ...
Treatment of Malaria Charles Mosler, PharmD, CGP, FASCP
... • Artesunate (2mg/kg qd) plus either tetracycline (4mg/kg q6h) or doxycycline (2mg/kg qd) or clindamycin (10mg/kg q12h) x 7 days OR • Quinine (10mg salt/kg q8h) plus either tetracycline (4mg/kg q6h) or doxycycline (2mg/kg qd) or clindamycin (10mg/kg q12h) x 7 days • Quinine is poorly tolerated with ...
... • Artesunate (2mg/kg qd) plus either tetracycline (4mg/kg q6h) or doxycycline (2mg/kg qd) or clindamycin (10mg/kg q12h) x 7 days OR • Quinine (10mg salt/kg q8h) plus either tetracycline (4mg/kg q6h) or doxycycline (2mg/kg qd) or clindamycin (10mg/kg q12h) x 7 days • Quinine is poorly tolerated with ...
Cataflam® Voltaren® Voltaren
... therapy is to use a starting dose likely to be effective for the majority of patients and to adjust dosage thereafter based on observation of diclofenac’s beneficial and adverse effects. In patients weighing less than 60 kg (132 lb), or where the severity of the disease, concomitant medication, or o ...
... therapy is to use a starting dose likely to be effective for the majority of patients and to adjust dosage thereafter based on observation of diclofenac’s beneficial and adverse effects. In patients weighing less than 60 kg (132 lb), or where the severity of the disease, concomitant medication, or o ...
obagi nu-derm system - Skincarehealthy.com
... has been shown to be teratogenic in rats when given in doses 1000 times the topical human dose. Oral tretinoin has been shown to be fetotoxic in rats when given in doses 500 times the topical human dose. Topical tretinoin has not been shown to be teratogenic in rats and rabbits when given in doses o ...
... has been shown to be teratogenic in rats when given in doses 1000 times the topical human dose. Oral tretinoin has been shown to be fetotoxic in rats when given in doses 500 times the topical human dose. Topical tretinoin has not been shown to be teratogenic in rats and rabbits when given in doses o ...
VICTOZA is contraindicated in patients with a personal or family history... carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type... ——— CONTRAINDICATIONS ———
... insulin may have an increased risk of hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Dosage and Administration (2.2), Adverse Reactions (6.1)]. 5.5 Renal Impairment VICTOZA® ...
... insulin may have an increased risk of hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Dosage and Administration (2.2), Adverse Reactions (6.1)]. 5.5 Renal Impairment VICTOZA® ...
Editor`s Pick: Targeted Agents in Patients with Metastatic Renal
... and 3, but also PDGFR-α and β, and others).31 The recommended dose resulting from a Phase I study, which showed a correlation between plasma concentrations of pazopanib and development of hypertension, was 800 mg/day.32 The safety profile of pazopanib is similar to that of sunitinib, but with a less ...
... and 3, but also PDGFR-α and β, and others).31 The recommended dose resulting from a Phase I study, which showed a correlation between plasma concentrations of pazopanib and development of hypertension, was 800 mg/day.32 The safety profile of pazopanib is similar to that of sunitinib, but with a less ...
Part10
... flavonoid content and therefore the identification and quantification of all the types of flavonoids consumed by humans is incomplete. Plants have evolved to produce flavonoids to protect against fungal parasites 寄生虫, herbivores 草食动物, pathogens, and oxidative cell injury. Dietary intake and food so ...
... flavonoid content and therefore the identification and quantification of all the types of flavonoids consumed by humans is incomplete. Plants have evolved to produce flavonoids to protect against fungal parasites 寄生虫, herbivores 草食动物, pathogens, and oxidative cell injury. Dietary intake and food so ...
Report of the WHO Informal Consultation on the use of Praziquantel
... Helminthiasis (8-14 October 2001), the participating experts felt that the current WHO recommendations to avoid using praziquantel during pregnancy and lactation and mebendazole or albendazole in children under two years of age, needed to be reviewed and possibly revised. The Committee recognized th ...
... Helminthiasis (8-14 October 2001), the participating experts felt that the current WHO recommendations to avoid using praziquantel during pregnancy and lactation and mebendazole or albendazole in children under two years of age, needed to be reviewed and possibly revised. The Committee recognized th ...
IDWeek 2015_Dalbavancin Poster #786_Van Anglen et al
... foot infection (11%) and implanted prosthetic device infection (4%). Forty nine pts (47%) had DAL therapy initiated in the POIC and 56 pts (53%) received DAL following hospitalization. Fifty-five pts (53%) received other intravenous antibiotics (IVABs) prior to treatment with DAL for a median of 5 d ...
... foot infection (11%) and implanted prosthetic device infection (4%). Forty nine pts (47%) had DAL therapy initiated in the POIC and 56 pts (53%) received DAL following hospitalization. Fifty-five pts (53%) received other intravenous antibiotics (IVABs) prior to treatment with DAL for a median of 5 d ...
Product Monograph Fomepizole for Injection 1.5 g / 1.5 mL (1 g/mL
... in human milk, nursing should be discontinued when Fomepizole is administered to nursing women. Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Fomepizole is metabolized by the liver and excreted by the kidney. The functions of both organs are ...
... in human milk, nursing should be discontinued when Fomepizole is administered to nursing women. Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Fomepizole is metabolized by the liver and excreted by the kidney. The functions of both organs are ...
The Dangers of Beta-Blockers and Epinephrine
... avoid all beta-blockers in patients who are at risk of anaphylaxis, including those receiving immunotherapy or those who carry epinephrine or self-injection. Recommendations Patients on nonselective beta-blockers should generally not receive a systemic dose of epinephrine if they are not already in ...
... avoid all beta-blockers in patients who are at risk of anaphylaxis, including those receiving immunotherapy or those who carry epinephrine or self-injection. Recommendations Patients on nonselective beta-blockers should generally not receive a systemic dose of epinephrine if they are not already in ...
product monograph epival
... EPIVAL® (divalproex sodium). These incidences usually occurred during the first 6 months of treatment with EPIVAL®. Caution should be observed when administering EPIVAL® to patients with a prior history of hepatic disease. Patients on multiple anticonvulsants, children, those with congenital metabol ...
... EPIVAL® (divalproex sodium). These incidences usually occurred during the first 6 months of treatment with EPIVAL®. Caution should be observed when administering EPIVAL® to patients with a prior history of hepatic disease. Patients on multiple anticonvulsants, children, those with congenital metabol ...
HYDROXYZINE
... 50–100 mg, repeat every 4–6 hours as needed • Hydroxyzine intramuscular injection should not be given in the lower or mid-third of the arm and should only be given in the deltoid area if it is well-developed • In adults, hydroxyzine intramuscular injections may be given in the upper outer quadrant o ...
... 50–100 mg, repeat every 4–6 hours as needed • Hydroxyzine intramuscular injection should not be given in the lower or mid-third of the arm and should only be given in the deltoid area if it is well-developed • In adults, hydroxyzine intramuscular injections may be given in the upper outer quadrant o ...
AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF
... diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m 2 body surface area basis. Amphet ...
... diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m 2 body surface area basis. Amphet ...
Data Sheet Name of Medicine Presentation SPRYCEL
... Experience with overdose of SPRYCEL in clinical studies is limited to isolated cases. The highest overdosage of 280mg per day for one week was reported in 2 patients and both developed a significant decrease in platelet count. Since SPRYCEL is associated with severe myelosuppression, patients who i ...
... Experience with overdose of SPRYCEL in clinical studies is limited to isolated cases. The highest overdosage of 280mg per day for one week was reported in 2 patients and both developed a significant decrease in platelet count. Since SPRYCEL is associated with severe myelosuppression, patients who i ...
What is the most appropriate antidepressant to use in persons with
... Depression is increased in people with epilepsy with a lifetime prevalence of about 30% (1). Patients with epilepsy are three times more likely to be prescribed an antidepressant than the general population and two times more likely to report suicidal thoughts (1). The association between epilepsy a ...
... Depression is increased in people with epilepsy with a lifetime prevalence of about 30% (1). Patients with epilepsy are three times more likely to be prescribed an antidepressant than the general population and two times more likely to report suicidal thoughts (1). The association between epilepsy a ...
Cataract development and outcome ofsurgery in bone marrow
... significant; nor was there any difference between sexes in development and degree of opacification. Multiple cataractogenic factors are involved in BMT. Radiation as a cause of cataract formation has been known for almost a century. In 1957 Merriam and Focht9 presented a clinical study of radiation ...
... significant; nor was there any difference between sexes in development and degree of opacification. Multiple cataractogenic factors are involved in BMT. Radiation as a cause of cataract formation has been known for almost a century. In 1957 Merriam and Focht9 presented a clinical study of radiation ...
Product Monograph - Ask Novartis Pharma
... increased risk of renal failure in this population (see DOSAGE AND ADMINISTRATION). Zoledronic acid has been associated with renal dysfunction manifested as deterioration in renal function, and acute renal failure (see ADVERSE REACTIONS-Clinical Trial Adverse Drug Reactions and Post-Market Adverse D ...
... increased risk of renal failure in this population (see DOSAGE AND ADMINISTRATION). Zoledronic acid has been associated with renal dysfunction manifested as deterioration in renal function, and acute renal failure (see ADVERSE REACTIONS-Clinical Trial Adverse Drug Reactions and Post-Market Adverse D ...
Clinical Toxicology: Part I. Diagnosis and Management of Common Drug Overdosage EY
... alteration in neurological, cardiovascular and respiratory functions. The differential diagnosis includes, central nervous system injury and metabolic encephalopathies (e.g. hepatic failure, hyponatraemia, hypocapnia, hypoglycaemia). In general, measures to prevent absorption (e.g. emesis, gastric l ...
... alteration in neurological, cardiovascular and respiratory functions. The differential diagnosis includes, central nervous system injury and metabolic encephalopathies (e.g. hepatic failure, hyponatraemia, hypocapnia, hypoglycaemia). In general, measures to prevent absorption (e.g. emesis, gastric l ...
Product Monograph August 25, 2016
... not handle ZYTIGA® 250 mg uncoated tablets without protection, e.g., gloves. Nursing Women: ZYTIGA® is not for use in women. It is not known if either abiraterone acetate or its metabolites are excreted in human breast milk. Pediatrics (< 18 years of age): ZYTIGA® has not been studied in children. ...
... not handle ZYTIGA® 250 mg uncoated tablets without protection, e.g., gloves. Nursing Women: ZYTIGA® is not for use in women. It is not known if either abiraterone acetate or its metabolites are excreted in human breast milk. Pediatrics (< 18 years of age): ZYTIGA® has not been studied in children. ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.